Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
about
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivityNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsNew antibody approaches to lymphoma therapyThe Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraNovel Drugs in Follicular LymphomaNovel CD20 monoclonal antibodies for lymphoma therapyA multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.The clinical development of obinutuzumab for the treatment of follicular lymphoma.A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysisA phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokineticsTarget Therapy in Hematological Malignances: New Monoclonal Antibodies.Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series.Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.The role of monoclonal antibodies in the treatment of lymphomas.Managing newly diagnosed follicular lymphoma: state of the art and future perspectives.The current status and future impact of targeted therapies in non-Hodgkin lymphoma.The optimal management of follicular lymphoma: an evolving field.How we manage follicular lymphoma.Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.Chemotherapy-free treatment in patients with follicular lymphoma.Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma.Ofatumumab in the treatment of non-Hodgkin's lymphomas.Breakthrough therapies in B-cell non-Hodgkin lymphoma.New targeted therapies for malignant lymphoma based on molecular heterogeneity.Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy ResponsePerspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.Targeting indolent non-Hodgkin lymphoma.Rituximab for the treatment of follicular lymphoma.Novel agents in indolent lymphomas.Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.
P2860
Q26773135-7FF87187-9A35-49DA-A4BF-DC7DE63EB433Q26782270-B8E32A63-87C2-43F0-88F3-E78B8524B7C3Q26849243-AE454FA0-056F-4C18-95DD-CEBD02BD18DBQ27022373-6AFAC40E-DCBA-42F8-9F5F-50042320E628Q28072397-457B5AAF-D218-4E90-893C-FE2958D8FF5CQ28076335-6FF2BF43-2924-4135-B39D-FC25637A9BA3Q28390112-2D0CB0AC-F3C3-49D8-88AA-4F41F7F9F49BQ33410306-BE26F462-B675-4457-82C8-192555181E99Q33565265-7BFADD6B-46AC-49D1-A148-0C54DB7ABEB0Q33626106-12FC252F-E1B3-4B59-BFDF-D6D20AAEF06FQ34725757-38F504B7-13C7-423E-B215-330B6738AA81Q35040896-6161DC02-E24D-47CD-9D3D-1D5E3EDB4CFBQ35142620-17C863BC-4FEA-4962-A68B-1ED6105A8B59Q36979140-F3D70301-3EC4-4562-A281-9D204EC676ECQ37046984-289FECA3-964E-4DC2-B744-3144744E28F4Q37118955-00E2D650-216A-49B5-B63D-EAD4303B36DDQ37178611-C49BB3CD-50AA-4933-93A4-4F8451E54661Q37524930-B595BB07-CDDF-4C6A-BF0D-86D70F4E9420Q38029382-07C6124C-898E-4ADA-9923-1D67B67E2A40Q38069595-FB63BE90-CA1D-4C54-A041-EBB042E139B2Q38088002-151575BF-93F4-4463-A223-912AD73AEE00Q38095123-3E1A2382-173D-414F-8178-EBDFC22E7CA6Q38124009-BE78F315-B4C1-4907-B5B5-E64A133A9EEBQ38191811-E6395718-AD44-4DFE-BD29-0E738EF00713Q38204975-0A84629C-85D4-4641-9CD4-068D310EB481Q38273851-FF141F0D-5E3F-4111-96FB-F4642ED450FAQ38317235-DEE71EBB-6B42-4D57-B577-E3D4380D5758Q38417140-12C99EC5-470C-4A4F-9CB9-58805F0ADDFCQ38434473-E6D9A85E-7995-4D4C-9258-68D625789249Q38516077-1E21CE3A-2F67-4A1B-AF60-5647BE339AEAQ38708600-BD4823E0-14AC-4F90-8EB3-B06BD02E2A15Q38787141-E18C0A06-C8AB-4544-BC9D-27BA1A1ABC74Q38876219-B5F1E3AA-D3CB-4185-89A5-0B64FF5F5E02Q38896113-88FCAEAD-0062-4C89-9A7E-4DFBFE7A301AQ38916526-22A70325-3186-42C7-8963-8C8E95BD716EQ38917848-F2B28EE1-4164-4A27-91BE-8CA5B923710DQ39360775-AE02500D-A46D-43D0-9CC7-47D511832D91Q39431412-1963A251-E5E3-42CB-AD7A-A0E363359910Q41387926-5E25AD41-EA81-4488-944B-C9F551A490A9Q41966195-51E9EF77-DC0A-4E7D-A3AC-AB78002770CF
P2860
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Ofatumumab monotherapy in ritu ...... ults from a multicenter study.
@ast
Ofatumumab monotherapy in ritu ...... ults from a multicenter study.
@en
type
label
Ofatumumab monotherapy in ritu ...... ults from a multicenter study.
@ast
Ofatumumab monotherapy in ritu ...... ults from a multicenter study.
@en
prefLabel
Ofatumumab monotherapy in ritu ...... ults from a multicenter study.
@ast
Ofatumumab monotherapy in ritu ...... ults from a multicenter study.
@en
P2093
P50
P1433
P1476
Ofatumumab monotherapy in ritu ...... sults from a multicenter study
@en
P2093
405 Study Investigators
Andrzej Hellmann
Anton Hagenbeek
Charlotte A Russell
Christine G DiRienzo
Eric Jacobsen
Eve Gallop-Evans
Kazimierz Kuliczkowski
Lauren Pinter-Brown
P304
P356
10.1182/BLOOD-2011-09-378323
P407
P577
2012-03-02T00:00:00Z